<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50189">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01798329</url>
  </required_header>
  <id_info>
    <org_study_id>ETOS</org_study_id>
    <nct_id>NCT01798329</nct_id>
  </id_info>
  <brief_title>ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study</brief_title>
  <acronym>ETOS</acronym>
  <official_title>Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Padua</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <authority>Italy: National Bioethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is:

        -  Epidemiological/observational: investigating the presence of neuropsychological and
           electrophysiological alterations, suggesting a condition of minimal hepatic
           encephalopathy(and its behavioral correlates), in childhood and young adulthood
           affected by pre-hepatic portal hypertension due to portal vein thrombosis, even for
           implementing specific diagnostic protocols.

        -  Interventional: collecting preliminary data on the effects of a probiotic, in order to
           implement a controlled clinical study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiological/observational study investigating the presence of neuropsychological and
      electrophysiological alterations, suggesting a condition of minimal hepatic
      encephalopathy(and its behavioral correlates), in childhood and young adulthood affected by
      pre-hepatic portal hypertension due to portal vein thrombosis, even for implementing
      specific diagnostic protocols
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>neuropsychological and electrophysiological aspects</measure>
    <time_frame>after 15 weeks of probiotic or placebo treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement in the spectrum of the digitalised electroencephalogram, improvement in the performance of the psychometric tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>biochemical blood test</measure>
    <time_frame>after 15 weeks of probiotic or placebo treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Decreased level of serum ammonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine and faeces analysis</measure>
    <time_frame>after 15 weeks of probiotic or placebo treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdomen scan with color doppler technique</measure>
    <time_frame>after 15 weeks of probiotic or placebo treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurological evaluation</measure>
    <time_frame>after 15 weeks of probiotic or placebo treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dietary anamnesis (last three days)</measure>
    <time_frame>after 15 weeks of probiotic or placebo treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bowel frequency and characteristics</measure>
    <time_frame>after 15 weeks of probiotic or placebo treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic VSL#3 for 15 weeks, dosage variations according to the weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects treated with placebo for 15 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotic VSL#3</intervention_name>
    <description>VSL#3 is a probiotic that reduces:
urease faecal activity
faecal pH
inflammatory cytokine</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  extra-hepatic portal vein thrombosis

          -  4-20 years

          -  knowledge of italian language

          -  absence of perceptive or communicative deficit

          -  absence of psychiatric disease or mental retardation

        Exclusion Criteria:

          -  medical contraindications for required evaluations

          -  infective pathologies

          -  parenchymal hepatic pathologies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lorenzo D'Antiga, MD</last_name>
    <phone>+39 0352673856</phone>
    <email>ldantiga@hpg23.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ave Maria Biffi, psychologist</last_name>
    <phone>+39 0352674482</phone>
    <email>abiffi@hpg23.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorenzo D'Antiga, MD</last_name>
      <phone>+39 0352673856</phone>
      <email>ldantiga@hpg23.it</email>
    </contact>
    <investigator>
      <last_name>LORENZO D'ANTIGA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MICHELA BRAVI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>VALERIA CASOTTI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARA COLUSSO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARCO PEZZANI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>LORELLA CAFFI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>EMILIO UBIALI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARIA SIMONETTA SPADA, PSYCHOLOGIST</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>AVE MARIA BIFFI, PSYCHOLOGIST</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SILVIA BULLA, PSYCHOLOGIST</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>PAOLA PREVITALI, PSYCHOLOGIST</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>VERONICA FACCHINETTI, PSYCHOLOGIST</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CRISTINA MORO, PSYCHOLOGIST</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Padua</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis. 2004 Dec;19(3-4):253-67. Review.</citation>
    <PMID>15554421</PMID>
  </reference>
  <reference>
    <citation>Amodio P, Campagna F, Olianas S, Iannizzi P, Mapelli D, Penzo M, Angeli P, Gatta A. Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. J Hepatol. 2008 Sep;49(3):346-53. doi: 10.1016/j.jhep.2008.04.022. Epub 2008 Jun 2.</citation>
    <PMID>18602716</PMID>
  </reference>
  <reference>
    <citation>Amodio P, Marchetti P, Del Piccolo F, de Tourtchaninoff M, Varghese P, Zuliani C, Campo G, Gatta A, Gu√©rit JM. Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol. 1999 Aug;110(8):1334-44.</citation>
    <PMID>10454268</PMID>
  </reference>
  <reference>
    <citation>Amodio P, Del Piccolo F, Marchetti P, Angeli P, Iemmolo R, Caregaro L, Merkel C, Gerunda G, Gatta A. Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology. 1999 Jun;29(6):1662-7.</citation>
    <PMID>10347105</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 21, 2013</lastchanged_date>
  <firstreceived_date>February 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedali Riuniti di Bergamo</investigator_affiliation>
    <investigator_full_name>Dr. Lorenzo D'Antiga</investigator_full_name>
    <investigator_title>MD, Director of Pediatric Unit</investigator_title>
  </responsible_party>
  <keyword>Minimal Hepatic Encephalopathy</keyword>
  <keyword>Pre-hepatic Portal Hypertension</keyword>
  <keyword>portal vein thrombosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Brain Damage, Chronic</mesh_term>
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
